Gentium S.p.A. Hosts Symposium on Defibrotide at EBMT Annual Meeting

VILLA GUARDIA (COMO), Italy, April 2, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that the Company's lead product, Defibrotide, was the subject of a symposium, "How can defibrotide tackle two critical early complications of HSCT? Current and future concepts for prevention and treatment of GvHD and VOD," on April 1, 2012 at the 38th Annual Meeting of the European Group for Blood and Marrow Transplantation in Geneva, Switzerland.